"Development of a novel oral therapy that specifically targets IL-23R could potentially change the treatment paradigm” in moderate-to-severe plaque psoriasis (PsO), stated a Janssen R&D VP.
List view / Grid view
Janssen Research and Development
20 March 2014 | By Johnson & Johnson
Independent data monitoring committee recommends halting trial and unblinding data based on treatment efficacy...
7 January 2014 | By Johnson & Johnson
Janssen Research & Development, LLC today announced the early stopping of PCYC-1112-CA, the Phase 3 study of IMBRUVICA™ (ibrutinib) in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), based on the recommendation of an Independent Data Monitoring Committee (IDMC), which concluded that the study showed a significant…
New data at American Society of Hematology (ASH) Annuaul Meeting will offer important insights into safe and efficacious use of XARELTO®
3 December 2013 | By
XARELTO® is the most prescribed novel oral anticoagulant in the U.S. Market today...
New two-year results show SIMPONI® ARIA™ (GOLIMUMAB) for infusion inhibited radiographic progression in patients with active rheumatoid arthritis
28 October 2013 | By Johnson & Johnson
Nearly 70 percent of patients receiving SIMPONI ARIA at two years demonstrated ACR 20 response...
FDA Advisory Committee recommends approval of Simeprevir for combination treatment of genotype 1 chronic hepatitis C in adult patients
24 October 2013 | By Johnson & Johnson
Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration voted unanimously to recommend approval of the investigational protease inhibitor simeprevir...
Simeprevir Data from COSMOS study in Hepatitis C Patients accepted as late-breaking presentation at the annual meeting of the American Association for the Study of Liver Diseases (AASLD)
8 October 2013 | By Johnson & Johnson
Simeprevir works by blocking the protease enzyme that enables the hepatitis C virus to replicate in host cells...
Latest Phase 3 Results demonstrate safety profile of INVOKANA® (canagliflozin) as add-on therapy in the treatment of Type 2 Diabetes
24 September 2013 | By Janssen Research & Development, LLC
In patients inadequately controlled on metformin and a sulfonylurea, study results suggest canagliflozin improves glycemic control and was generally well tolerated, compared to placebo...
Simultaneous applications submitted to FDA and EMA for siltuximab for the treatment of MCD, a rare blood disorder
3 September 2013 | By Johnson & Johnson
“We’re proud of our work on siltuximab. As a rare disease with a small patient population, MCD is an area of significant unmet need”
Janssen Research & Development announces establishment of global cross-pharmaceutical clinical trial Investigator Databank
15 November 2012 | By Janssen Global Services
Lilly and Merck are first to join Janssen in this pre-competitive initiative to increase efficiencies in clinical trials...
6 August 2012 | By Pfizer
Bapineuzumab IV Phase 3 program discontinued...